Hologic, Inc. $HOLX Shares Purchased by Oak Thistle LLC

Oak Thistle LLC boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 182.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 62,629 shares of the medical equipment provider’s stock after purchasing an additional 40,444 shares during the quarter. Hologic comprises about 0.6% of Oak Thistle LLC’s holdings, making the stock its 6th largest position. Oak Thistle LLC’s holdings in Hologic were worth $4,665,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of HOLX. Winnow Wealth LLC acquired a new position in shares of Hologic during the 3rd quarter valued at about $26,000. Root Financial Partners LLC purchased a new position in Hologic in the 3rd quarter worth approximately $27,000. Harbor Capital Advisors Inc. purchased a new position in Hologic in the 4th quarter worth approximately $27,000. SJS Investment Consulting Inc. boosted its stake in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 168.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 310 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $76.01 on Wednesday. The firm has a market cap of $16.97 billion, a price-to-earnings ratio of 31.67, a P/E/G ratio of 2.24 and a beta of 0.70. The business’s 50-day simple moving average is $75.31 and its 200-day simple moving average is $73.83. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $76.07.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the business earned $0.87 EPS. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and decreased their price target for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Two equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $78.42.

Key Headlines Impacting Hologic

Here are the key news stories impacting Hologic this week:

• Positive Sentiment: Blackstone and TPG completed the $17 billion take‑private acquisition of Hologic at $79.00 per share, so public shareholders receive the deal consideration and the company will be delisted. Hologic (HOLX) Goes Private
• Positive Sentiment: Official press release confirming close and leadership transition — private equity owners named Joe Almeida as CEO to lead Hologic under Blackstone/TPG ownership. This clarifies post‑deal management and reduces execution uncertainty. Blackstone and TPG Complete Acquisition
• Neutral Sentiment: Company announcement/confirmations of the takeover and leadership changes echoed across outlets (filings/PR). These are procedural confirmations of the already‑announced deal. Hologic Taken Private in Blackstone-TPG Acquisition
• Neutral Sentiment: Trading in HOLX was halted earlier for “news pending,” consistent with exchange protocol around a material deal close. That halt resolved with the deal confirmation. (No link — market notice)
• Negative Sentiment: Hologic will be removed from the S&P 500; Casey’s General Stores is being added to the index to replace HOLX. Removal from the index means ETFs and passive funds tracking the S&P will sell the shares — a temporary negative for short‑term liquidity, though offset by the cash‑out at $79. Casey’s General Stores (CASY) Shares Jump
• Negative Sentiment: Unusual options activity ahead of the close showed a surge in put purchases, indicating elevated hedging or bearish positioning prior to the announcement; such activity can signal uncertainty but is largely moot now that the deal closed. S&P 500 change coverage

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.